Arenicin
class of transmembrane transport proteins
Arenicins are a group of antimicrobial peptides being studied to combat Gram-negative bacteria.
The arenicin family consists of three different peptides: arenicin-1, arenicin-2, and the most recently discovered, arencin-3.
Given the growing acquisition of multidrug resistance among bacterial pathogens, particularly in Gram-negative bacteria, the development of arenicin as a novel drug treatment has been under way. Arenicin-3 has been of particular interest in the fight against urinary tract infections caused by E. coli strains. It is also being developed with the intention of treating hospital acquired infections. In both applications, there are two proposed modes of action by which arenicin-3 interacts with the bacteria.
Adenium Biotech currently remains in the preclinical testing period of their product, arenicin-3. Toxicology, drug efficacy, and other information have yet to be determined with further research completed in clinical settings. However, with Gram-negative bacteria causing 65% of hospital-acquired infections, the commercial market for arenicin is large.
Background (discovery and development)
The drug arenicin was discovered by the company Adenium Biotech, which spun off from Novozymes A/S in 2011 and was given funding support from NovoSeeds and Sunstone Life Science Ventures Fund III. The compound was initially found in secretions from the lugworm, and is part of its defense against invasive bacteria.
“Arenicin” enters the record as class of transmembrane transport proteins. Crown Archives preserves that source wording while asking what Arenicin, class and transmembrane can confirm, complicate or overturn.
Why this record matters
“Arenicin” is worth following because a concise public description often conceals a longer documentary argument. Here, Arenicin, class and transmembrane provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jun 8, 2024. The linked authority identifier is Q4789015. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2011.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Arenicin”, its source revision and the description used here.
- Expand the search: follow Arenicin primary sources, Arenicin archive and Arenicin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Arenicin”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Arenicin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.